Literature DB >> 8809836

Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease.

M Mogi1, M Harada, H Narabayashi, H Inagaki, M Minami, T Nagatsu.   

Abstract

Interleukin (IL)-1 beta , IL-2, IL-4, IL-6, epidermal growth factor (EGF), and transforming growth factor (TGF)-alpha were measured for the first time in ventricular cerebrospinal fluid (VCSF) from control non-parkinsonian patients, patients with juvenile parkinsonism (JP) and patients with Parkinson's disease (PD) by highly sensitive sandwich enzyme immunoassays. All cytokines were detectable in VCSF from control and parkinsonian patients, and the concentrations were much higher than those in lumbar CFS. The concentrations of IL-1 beta, IL-2, IL-4 and TGF-alpha in VCSF were higher in JP than those in controls (P < 0.05). In contrast, the concentrations of IL-2 and IL-6 in VCSF from patients with PD were higher than those from control patients (P < 0.05). These results agree with our previous reports, in which the cytokine levels were elevated in the striatal dopaminergic region of the brain from patients with PD. Since VCSF is produced in the ventricles, the alteration of cytokines in VCSF may reflect the changes of cytokines in the brain. Because cytokines play an important role as mitogens and neurotrophic factors in the brain, the increases in cytokines as a compensatory response may occur in the brain of patients of JP or PD during the progress of neurodegeneration. Increase in cytokines may contribute not only as a compensatory response but as a primary initiating trigger for the neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8809836     DOI: 10.1016/0304-3940(96)12706-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  168 in total

1.  Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron.

Authors:  Moussa B.H. Youdim; Edna Grünblatt; Yona Levites; Gila Maor; Silvia Mandel
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

Review 2.  Glial cell response: A pathogenic factor in Parkinson's disease.

Authors:  Du Chu Wu; Kim Tieu; Oren Cohen; Dong-Kug Choi; Miquel Vila; Vernice Jackson-Lewis; Peter Teismann; Serge Przedborski
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

3.  Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray.

Authors:  Silvia Mandel; Edna Grünblatt; Gila Maor; Moussa B H Youdim
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

4.  Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probenecid model of Parkinson's disease.

Authors:  Annadurai Anandhan; Musthafa Mohamed Essa; Thamilarasan Manivasagam
Journal:  Neurotox Res       Date:  2012-06-06       Impact factor: 3.911

5.  Testing NF-κB-based therapy in hemiparkinsonian monkeys.

Authors:  Susanta Mondal; Avik Roy; Arundhati Jana; Sankar Ghosh; Jeffrey H Kordower; Kalipada Pahan
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-03       Impact factor: 4.147

6.  NF-κB in Aging and Disease.

Authors:  Jeremy S Tilstra; Cheryl L Clauson; Laura J Niedernhofer; Paul D Robbins
Journal:  Aging Dis       Date:  2011-12-02       Impact factor: 6.745

Review 7.  The executioners sing a new song: killer caspases activate microglia.

Authors:  J L Venero; M A Burguillos; P Brundin; B Joseph
Journal:  Cell Death Differ       Date:  2011-08-12       Impact factor: 15.828

8.  PINK1 stimulates interleukin-1β-mediated inflammatory signaling via the positive regulation of TRAF6 and TAK1.

Authors:  Hyun Jung Lee; Sung Hee Jang; Hyeyoung Kim; Joo Heon Yoon; Kwang Chul Chung
Journal:  Cell Mol Life Sci       Date:  2012-05-29       Impact factor: 9.261

9.  Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease.

Authors:  W Le; D Rowe; W Xie; I Ortiz; Y He; S H Appel
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

Review 10.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.